A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " LSI Medience Corporation

LSI Medience Corporation

Table of Contents

LSI Medience Corporation is a contract research organization providing GLP-compliant non-clinical studies. These studies are conducted at the LSIM Safety Science Institute, a consolidated subsidiary. Through testing performed within its own group facilities, the company supports the delivery of high-quality data that meets international regulatory standards.

Features of LSI Medience Corporation’s Non-clinical Contract Services

Highly reliable GLP-compliant testing framework

LSIM Safety Science Institute—the subsidiary responsible for non-clinical studies—has obtained multiple GLP certifications, including Pharmaceuticals GLP. The institute is highly regarded by third-party authorities such as Japan’s Ministry of Health, Labour and Welfare, the Ministry of Agriculture, Forestry and Fisheries, the Ministry of the Environment, as well as being recognized as compliant with OECD principles.

Within its in-house facilities, LSI Medience Corporation has established a system capable of conducting world-class safety studies for pharmaceuticals, agrochemicals, and chemical substances.

Comprehensive non-clinical capabilities including toxicology and pharmacokinetics

LSIM Safety Science Institute conducts a broad spectrum of non-clinical studies— toxicity testing (acute, repeated-dose, reproductive and developmental, and genotoxicity) , pharmacokinetics, metabolite identification, and analytical method validation.

A wide range of animal species can be used, including rats, mice, dogs, monkeys, and rabbits. Study designs can be customized to meet various regulatory and submission requirements. The institute supports development not only for pharmaceuticals but also agrochemicals and chemical substances across different development stages.

Strong compliance with global regulations and robust quality documentation

Because LSIM Safety Science Institute adheres to OECD guidelines in addition to Japanese GLP, it is capable of conducting studies intended for international joint development programs and overseas regulatory submissions.

The institute maintains an internal Quality Assurance department that ensures rigorous quality control, including audits and reporting. Study protocols and final reports can also be prepared in English, providing strong support for documentation required by international regulatory agencies.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models Available at LSI Medience Corporation

Pathological models for pain and inflammation assessment

As part of their pharmacology testing services, LSIM Safety Science Institute conducts non-clinical studies using various pathological models designed for the evaluation of pain and inflammation.

In their animal models, they analyse the efficacy of anti-inflammatory agents, analgesics, and other candidate compounds. Pharmacological effects—including mechanism of action, dose-response curve, and duration of the effect—are evaluated to support a smooth transition to the next clinical development stages.

Details regarding specific model protocols can be discussed during preliminary consultations.

Reference: LSI Medience Corporation Official Website https://www.ankaken.dmsv.tokyo/test/pharmacology.html

LSI Medience Corporation Non-clinical Case Studies

DMPK characterization support for drug candidate compounds

The official website does not currently provide publicly available case study information.

LSI Medience Corporation Company Information

Address	3-30-1 Shimura, Itabashi-ku, Tokyo
Tel	03-5994-2111
Website	https://www.medience.co.jp/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us